GARIMA ARORA: Open Payments
NPI 1497043137 · SUGAR LAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$657 in 39 payments from 12 companies in 2025. Trend: 2023 $922 · 2024 $1,024 · 2025 $657
Food & beverage: $657
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $206 |
| ABBVIE INC. | 4 | $94 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $69 |
| Neurocrine BioSciences, Inc. | 2 | $47 |
| Abbott Laboratories | 2 | $41 |
| Biogen, Inc. | 2 | $41 |
| Azurity Pharmaceuticals, Inc. | 2 | $39 |
| ACADIA Pharmaceuticals Inc | 2 | $38 |
| UCB, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
Products named: TRINTELLIX, CAPLYTA, HYQVIA, INGREZZA, PROCLAIM, TYSABRI, HORIZANT, VRAYLAR.
Industry payments across TX — which companies pay providers there.
